Autonomix Medical, Inc. commences trading on Nasdaq

Autonomix Medical, Inc. announced its common stock will begin trading on the Nasdaq, Monday, January 29, 2024 at approximately 10:30 am EST under the ticker symbol “AMIX.”

Lori Bisson, Chief Executive Officer of Autonomix, commented, “The successful closing of our IPO and trading on Nasdaq is a momentous milestone and the first step toward strengthening our market position. Nasdaq provides a platform of enhanced visibility, liquidity and expanded shareholder base that we believe will play a key factor for the Company moving forward. We are dedicated to dramatically improving the quality of millions of lives by empowering the nerve-directed treatments of tomorrow and we have positioned the Company to achieve transformational corporate and development milestones in 2024. We are committed to building shareholder value and look forward to providing additional updates on our development progress.”

The Company’s catheter-based sensing technology is being developed to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment. Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.
MB Bureau